Chemotherapy Extends Life in Prostate Cancer (cont.)
As in Study 1, more patients in the groups treated with docetaxel experienced a drop in their PSA levels compared to the prednisone and mitoxantrone group, said principal investigator Mario Eisenberger, M.D., of Johns Hopkins University in Baltimore.
On the basis of this study's findings, the U.S. Food and Drug Administration recently approved docetaxel, in combination with prednisone, to treat advanced prostate cancer that is no longer responding to hormonal therapy. The SWOG trial (Study 1) provided additional data to support the approval.
As a result of these findings, however, "docetaxel is definitely a new standard of care" for patients with advanced prostate cancer that is resistant to hormone therapy, said Petrylak.
"These results are a reason for celebration as well as for optimism for the
future," added Eisenberger. They put to rest concerns that advanced prostate
cancer would not respond to chemotherapy, he said. In an extremely severe
disease such as advanced prostate cancer, he added, a treatment must be very
effective to achieve a two- to three-month increase in median survival.
Last Editorial Review: 11/12/2004